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Summary
An approach has been optimized permitting measurement of human cytokine reporter gene
expression aftertransient transfection directly into purified humanperipheral blood T lymphocytes.
Comparing the expression of interleukin 2 (I,2) CAT with a series of specially engineered y
interferon (IFN-'y) constructs, a fundamental difference in the molecular mechanisms regulating
these two cytokines has been suggested. A potent, tissue-specific, constitutive-acting positive
regulatory element was located between sequences -215 and -53 in the human IFN-'y gene.
Deletion analyses suggested that sequences slightly upstream, between positions -251 to -215,
exerted a powerful dominant suppressive influence over that positive element. Negative elements
appear to play a major role in controlling the regulation of human IFN-'y gene expression. We
thus propose a model of cytokine gene regulation in which selective derepression may be an
important fundamental mechanism of induction and/or positive modulation.
M
olecular genetic analyses of human cytokine regulation
have traditionally involved the study of T cell clones
and/or T cell tumor lines, perhaps our best genetic model
being IIr2 (1-3). T cell clones, however, have not proven com-
pletely reliable as cellular models, and T cell tumor lines are
often variable in both the quality and quantity of theircytokine
responses (4, 5). Further, recent studies of primary lympho-
cyte subsets now suggest fundamental differences in the ex-
pression of1172 compared with other differentially expressed
cytokines including IFN-.y (6-8). To investigate these and
other issues ofdifferential cytokine regulation, we have initi-
ated a genetic approach involving transient transfection of
cytokine reporter constructs directly into T lymphocytes
purified from human peripheral blood. Using this technology
we have investigated human IFN--y as an important genetic
model of a highly interactive, easily modulateable, and clini-
callyrelevant human cytokine (9-13). Based on our findings,
we now propose an alternative modelof human cytokine ex-
pression that evokes gene derepression as the basic mecha-
nism underlying cytokine induction.
Primary human T cells free of CD11' cells were purified by
double-panning and E-rosetting of normal, seronegative human
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PBMCs (10, 14). T cells cultured in 1.0 14g/ml. PHA for 12- 18 h
at 3 x 106 cells/ml became transfection competent yet made no
IIr2 and <5.0 U of IFN-y per 106 cells. 6 x 106 cells and indi-
cated supercoiled plasmid DNAs at 50 p.g/ml were electroporated
in 0.3 ml ofRMPI/10% FCS at 250 V, 980 p.F using a Progenitor
II (Hoefer Scientific Instruments, San Francisco, CA) wired to an
electroporation chamber (Bio-Rad Laboratories, Richmond, CA).
Cellswere activated 2 hlaterwith 1.0,ug/ml ofPHA and 10 ng/ml
ofPMA in freshRPMI/10% FCS. 48 h afteractivation, cells were
analyzed for production ofIFN-y by RIA (Centecor, Malvern, PA),
IL2 by CTLL analyses (1), and CAT as described (15) (except that
CAT reactions were allowed to proceed overnight).
IFN-y CAT construct pIFN-697 was made by subcloning the
5' sequences, -697 to +14, from the human genomic clone
pB9KB-1 (donated by Dr. Pat Gray, Genentech, So. San Francisco,
CA), into an empty CAT vehicle (pBR CAT) made by deleting
all RSV sequences from RSV CAT (16) with Ndel/HindIII (Fig.
1 C). Constructs -347, -251, -215, and -170 were made by
5' to 3' EXO III deletions of pIFN-697. Constructs -347&, 287_33,
-251m 162-53, and -215m 110 .53, were similarly engineered using
internal unidirectional EXO III digestion. Human 11,2 CAT (1)
was generously donated by Dr. Jerald Crabtree, Stanford Univer-
sity, Stanford, CA. O-actin CAT was kindly provided by Drs. Art
Sands and Bob Schwartz of Baylor College of Medicine. Unlike
the traditional viral enhancer constructs RSVCAT and SV2CAT,
S-actin CAT was consistently unaffectedby signals ofT cell activa-
tion. Transfections were controlledfor cell number, extract volume,
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661-664and quantity of plasmid DNA, and quantitated as molar equiva-
lents of acetylated chloramphenicol produced by test plasmids rela-
tive to control plasmid pBR CAT
Results and Discussion
As shown in Fig. 1 A and Table 1, IL2 CAT had no
significant activity in primary resting (PHA only) T cells,
yet was upregulated nearly 10-fold after PHA/PMA treat-
ment oftransfected cells . 0-actin CAT had identical high ac-
tivity in both resting and activated cells, while pBR-CAT
had only baseline activity (Fig . 1 A) .
Representative transfections of pIFN-697-derived constructs
into primary human T cells are shown qualitatively in Fig .
1 B and quantitatively in Table 1 . Resting peripheral blood
T cells expressed considerable CAT activity (4-15-fold over
background) after transient transfection with this construct .
This phenomenon was recapitulated in resting Jurkat cells
(data not shown), as well as in a resting murine T cell line
transfected with an IFN-.y -550 CAT construct (17) . No
IL-2 CAT activity was noted in resting primary T cells and
no substantial release of IL2 or IFN --y occurred. Transfected
cells subsequently aestivated with PHA/PMA increased pIFN-
697 CAT activity an additional two- to fivefold (Fig. 1 B
and Table 1), upregulated IL2 CAT activity about eightfold
(Fig. 1 A and Table 1), and routinely produced 40-200 U
ofIFN-y and 40-100U of IL2 per 106 cells. Our data thus
suggest that sequences in the proximal upstream region (-697
to +14) of the human IFN - 'y gene, unlike those in IL2, re-
spond positively in trans to signals already present in minimally
activatedT cells. Presumably, additional negative regulatory
sequences must prevent such baseline gene expression from
occurring in the endogenous IFN --y gene .
Figure 1 .
￿
PHA-treated human PBLs were transfected with (A) con-
trol plasmids: pBR ; a promoterless CAT construct ; IL2, 11,2 CAT
and (3-actin CAT,,' (B) IFN-'Y expression constructs : -697, pIFN-697
CAT ; -347, pIFN-347 CAT ; -251, pIFN-251 CAT; -215, IFN-215
CAT as shown in C . (+) Cells activated with PHA/PMA; (-)
media only.
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Table 1 .
￿
Induction' ofHuman IFN-y CAT Vectors
Transiently Transfected into Human Peripheral T Cells
Fold induction compared with control plasmid pBR .
t Cells blasted 16-18 h with PHA .
S Cells blasted 16-18 h with both PHA and PMA .
II (+ ) Stimulation with PHA/PM after transfection .
( - ) Incubation with media alone after transfection .
Deleting base pairs -697 to -348 (pIFN-347) dramati-
cally diminished both resting transcription as well as upregu-
lation by PHA/PMA (Fig. 1 B and Table 1) . Further dele-
tions to position -251 behaved similarly (Fig. 1 B and Table
1), suggesting positive cis-acting elements upstream of posi-
tion -348 . However, when 36 additional 5' by were deleted
(construct -215), high level constitutiveCAT activity (5-60-
fold over baseline) consistently reappeared in transfected pri-
mary T cells (Fig. 1 B and Table 1) . The -215 construct
also directed high level constitutive transcription in Jurkat
cells (data not shown) . In two experiments, the high base-
line activity was even further upregulated byPHA/PAM (Table
1, Exps . 2, 3) . Deleting to position -170 did not significantly
PHA/PMA 1#
Experiment
2t 3t 4S
-697 + 11 40.1 10.5 10.7
- 1 14.9 5.4 4.2
-347 + 6.2 2.5
- 3.5 2.4
-251 + 3.1 1 .3 2.0
- 3.9 0.7 1 .6
-215 + 57.3 25.1 10.7 32.6
- 60.8 9.5 5 .4
-170 + 22.0 55.3
- 7.6
-52 + 1 .2 0.8
- 1 .3
-215 0(162-53) + 1 .3 1.1
- 1 .6
- 215 0(110-53) + 0.9
pIL-2 CAT + 12.8 6.1
- 1 .7 0.7
po-actin CAT + 159.0 84.7
- 137.0
pBR CAT + 0.6 0.8 1 .1 1 .0
- 1.4 1.1 0.9Figure 2 .
￿
Peripheral T cells (T) and Raji B cells (B) were trans-
fected with the following DNAs as described: pBR CAT, p(3-actin
CAT, or pIFN-215 CAT. No secondary activating signals were used .
reduce this region's positive transcriptional influence (Table
1, Exps. 2, 4), but deleting to position - 52 (IFN-y
CAAT/TATA promoter only) completely abolished all CAT
activity (Table 1, Exps. 2,4) . By internally deleting sequences
within the -215 construct (Table 1, Exps . 3, 4), sequences
between positions -110 and -53 wereshown to be required
for that activity. TheT cell specificity of the -215 construct
was further demonstrated by its lack of transcriptional ac-
tivity in either theB cell line, Raji (Fig . 2) orNIH3T3 cells
(data not shown) . Of note, DNAse I footprinting studies
in progress have now demonstrated a double strand, T cell-
specific footprint over the sequence GTCTAAAGGAAAC-
TCTAACTACAACACC, which is within that region at po-
sitions -172 to -156 .
Our preliminary findings of apparent positive and induc-
ible elements upstream of position -348 in the IFN-y pro-
moter region corroborate our most recent observations (17)
on that gene's induction . However, our higher resolution dele-
tional analyses now point to additional constitutive enhancer-
like elements which are proximally located (position -215
to -53), T cell specific, and apparently dominantly suppressed
by more upstream regulatory elements presumably between
positions -251 and -215 . Perhaps related, that latter region
contains a sequence AGAATCCCAC which has identity to
the consensus sequence RRRRTTYCAY found in the 5'
flanking region of the human 11,2, GM-CSF, IIr4, and G-CSF
genes (3) . Thus, several separate lines of functional evidence
strongly support the notion that negative elements control
the regulation ofhuman IFN-y gene expression . Addition-
glly, more recent studies in our laboratories have uncovered
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Figure 3 .
￿
Model of human IFN-y gene regulation as diagrammed
with the positions of the exons (filled rectangles) and DNAse I hyper-
sensitive sites (DH, arrows) shown . Constitutive DH sites have been
previously located 2,800 by upstream of the promoter (circled P) and
in the first intron adjacent to a tissue nonspecific enhancer (11, 17,
18) . T cell activation induces a third DH site just proximal to the
promoter. Regulatory elements contained in this region are as indi-
cated : a proximal, constitutively active, and T cell-specific positive
element (crosshatched), and a proximal dominant negative element of
undetermined tissue specificity (open box with - sign) . More up-
stream elements (open box, ±) involved in resting activity and up-
regulation, also containing an additional T cell-specific and potent,
negative regulatory element .
aT cell-specific, orientation-dependent silencer element within
the -550 to -347 region of the IFN-y gene (unpublished
observations) . Since only one report in the literature supports
the notion of negative regulatory elements anywhere in the
IIr2 gene (3), our composite data might be appropriately
rectified by a slightly different model of cytokine gene in-
ducibility (Fig . 3) than that envisioned for 1172 . It is hypothe-
sized that transcription of the human IFN-y gene is dom-
inantly suppressed in mature restingT cells by several negative
regulatory elements . Further,we propose that induction and
modulation of that cytokine's gene expression may involve
selective derepression of such suppressive influences along ei-
ther contiguous or discontiguous regions within the human
IFN-y locus . This would facilitate constitutive upregulation
of IFN-y gene transcription via the potent constitutive 5'
upregulatory element described herein and/or the intronic
enhancer elements we recently described (9, 11, 17, 18) . It
is noteworthy that such a model was recently proposed to
explain the regulation ofboth IFN-c i and -a genes inhuman
(19, 20) . Further, removal of inhibitory influence by normal
activating signals is thought to be the mechanism by which
NF-KB responsive genes are activated (21) . Understanding
such reciprocal mechanisms will be an important first step
in the development of epigenetic approaches to modulating
such intercellular pathways .
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